Combat Medical raises £2.6M to push bladder cancer therapy into late-stage testing
Combat Medical, a UK-based bladder cancer innovator, has secured a fresh £2.6 million funding round to reach a crucial phase 3 milestone for its lead therapy. The capital will be used to accelerate late-stage clinical development of the company’s heat-enhanced intravesical treatment, designed for patients with non-muscle invasive bladder cancer who face limited options after standard care fails.
Aiming to transform non-muscle invasive bladder cancer care
Bladder cancer is one of the most recurrent malignancies worldwide, placing a heavy burden on patients and healthcare systems. Many patients with non-muscle invasive disease receive standard intravesical therapies such as BCG, yet a substantial proportion relapse. Combat Medical is developing a technology that combines drug delivery with controlled heat, a method known as hyperthermic intravesical chemotherapy, to enhance drug penetration and tumour kill while aiming to preserve the bladder.
The newly raised £2.6 million will support completion of a pivotal phase 3 study designed to generate robust evidence on efficacy, safety and recurrence rates. Hitting this milestone is expected to be critical for future regulatory submissions and potential reimbursement discussions in major markets.
Investors back late-stage oncology innovation
The funding round reflects growing investor interest in targeted oncology platforms that can improve outcomes without resorting to radical surgery. While specific backers were not disclosed in the source text, the investment underlines confidence in Combat Medical’s clinical data to date and its ability to execute a complex, multicentre phase 3 programme.
Industry observers note that bladder preservation strategies are becoming an important focus in oncology, as payers and clinicians seek interventions that reduce hospital stays, lower long-term costs and maintain quality of life. If successful, Combat Medical’s heat-assisted intravesical therapy could offer a new standard of care for patients at high risk of recurrence, and position the company as a leading player in the global bladder cancer treatment market.
Next steps in clinical and commercial strategy
With funding secured, Combat Medical is expected to prioritise patient enrolment, data collection and regulatory engagement. Positive phase 3 results could open the door to partnerships with large pharmaceutical and medical device companies, enabling broader commercial rollout and faster access for patients facing this challenging disease.